These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 19152412)

  • 21. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
    Kieffer TL; Sarrazin C; Miller JS; Welker MW; Forestier N; Reesink HW; Kwong AD; Zeuzem S
    Hepatology; 2007 Sep; 46(3):631-9. PubMed ID: 17680654
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa.
    Zeuzem S; Lee JH; Roth WK
    Hepatology; 1997 Mar; 25(3):740-4. PubMed ID: 9049228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutations in the interferon sensitivity-determining region (nonstructural 5A amino acid 2209-2248) in patients with hepatitis C-1b infection and correlating response to combined therapy of pegylated interferon and ribavirin.
    Yen YH; Hung CH; Hu TH; Chen CH; Wu CM; Wang JH; Lu SN; Lee CM
    Aliment Pharmacol Ther; 2008 Jan; 27(1):72-9. PubMed ID: 17973647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.
    Sarrazin C; Rouzier R; Wagner F; Forestier N; Larrey D; Gupta SK; Hussain M; Shah A; Cutler D; Zhang J; Zeuzem S
    Gastroenterology; 2007 Apr; 132(4):1270-8. PubMed ID: 17408662
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HVR-1 heterogeneity during treatment with telaprevir with or without pegylated interferon alfa-2a.
    Lange CM; Susser S; Herrmann E; Karey U; Kieffer TL; Kwong AD; Schinkel J; Reesink HW; Zeuzem S; Sarrazin C
    Scand J Gastroenterol; 2011 Nov; 46(11):1362-8. PubMed ID: 21815864
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The response to pegylated interferon alpha 2a in haemodialysis patients with hepatitis C virus infection.
    Akhan SC; Kalender B; Ruzgar M
    Infection; 2008 Aug; 36(4):341-4. PubMed ID: 18629437
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
    Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
    J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mutations in carboxy-terminal part of E2 including PKR/eIF2alpha phosphorylation homology domain and interferon sensitivity determining region of nonstructural 5A of hepatitis C virus 1b: their correlation with response to interferon monotherapy and viral load.
    Ukai K; Ishigami M; Yoshioka K; Kawabe N; Katano Y; Hayashi K; Honda T; Yano M; Goto H
    World J Gastroenterol; 2006 Jun; 12(23):3722-8. PubMed ID: 16773689
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of pegylated interferon-alpha-2a and ribavirin concentrations in sustained viral response in HCV/HIV-coinfected patients.
    Lopez-Cortes LF; Valera-Bestard B; Gutierrez-Valencia A; Ruiz-Valderas R; Jimenez L; Arizcorreta A; Terrón A; Viciana P
    Clin Pharmacol Ther; 2008 Nov; 84(5):573-80. PubMed ID: 18596682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The efficacy of pegylated interferon alpha 2a or 2b plus ribavirin in chronic hepatitis C patients.
    Yenice N; Mehtap O; Gümrah M; Arican N
    Turk J Gastroenterol; 2006 Jun; 17(2):94-8. PubMed ID: 16830289
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rapid virological response in peripheral blood mononuclear cells with an increase of hepatitis C virus-specific interferon-gamma production predisposes to sustained virological response in patients with chronic hepatitis C genotype 1 undergoing treatment with pegylated-interferon alpha 2a plus ribavirin.
    Perrella A; Sbreglia C; Atripaldi L; Esposito C; D'Antonio A; Perrella O
    Scand J Gastroenterol; 2010; 45(2):250-5. PubMed ID: 19968615
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations in the E2-PePHD and NS5A region of hepatitis C virus type 1 and the dynamics of hepatitis C viremia decline during interferon alfa treatment.
    Berg T; Mas Marques A; Höhne M; Wiedenmann B; Hopf U; Schreier E
    Hepatology; 2000 Dec; 32(6):1386-95. PubMed ID: 11093746
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lack of clinical evidence for involvement of hepatitis C virus interferon-alpha sensitivity-determining region variability in RNA-dependent protein kinase-mediated cellular antiviral responses.
    Mihm S; Monazahian M; Grethe S; Meier V; Thomssen R; Ramadori G
    J Med Virol; 2000 May; 61(1):29-36. PubMed ID: 10745229
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
    von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
    Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of hepatitis C in hemodialysis patients with pegylated interferon alpha-2a as monotherapy.
    Sikole A; Dzekova P; Selja N; Gaseva M; Nikolov IG; Zabzun M; Muharemi S; Asani A; Amitov V; Mena S; Grunevska V; Ivanovski L; Polenakovic M
    Ren Fail; 2007; 29(8):961-6. PubMed ID: 18067041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
    Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A
    Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mutations in different regions of the genome of hepatitis C virus genotype 1b and association with response to interferon therapy.
    Zhang L; Han F; Zhang D; Dou XG
    Int J Mol Med; 2012 Dec; 30(6):1438-42. PubMed ID: 23064792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mutations in hepatitis C virus genotype 1b and the sensitivity of interferon-ribavirin therapy after liver transplantation.
    Fukuhara T; Taketomi A; Okano S; Ikegami T; Soejima Y; Shirabe K; Maehara Y
    J Hepatol; 2010 May; 52(5):672-80. PubMed ID: 20346532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutations in ISDR of NS5A gene influence interferon efficacy in Chinese patients with chronic hepatitis C virus genotype 1b infection.
    Shen C; Hu T; Shen L; Gao L; Xie W; Zhang J
    J Gastroenterol Hepatol; 2007 Nov; 22(11):1898-903. PubMed ID: 17914967
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.